Editorial Board
Jonathan Riess
University of California, Davis Medical School · United States
Editorial leadership for Journal of Lung Cancer Epidemiology
Research interests
- Lung Cancer Developmental Therapeutics
- Translational Research
- Thymic Malignancies
Biography
- Jonathan Riess, MD, MS is an oncologist interested in clinical trials and translational research to help develop new treatments for lung cancers and thymic malignancies.
- He completed his medical degree at Robert Wood Johnson Medical School, residency in Internal Medicine at University of California San Francisco, and fellowship in Oncology and Hematology along with a Masters degree in Epidemiology and Clinical Research at Stanford University School of Medicine.
- He is a member of ASCO, AOA, IASLC, SWOG and the California Cancer Consortium.
Selected publications
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% 2021 cited 983×
- Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 2023 cited 169×
- Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer 2024 cited 81×
- Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC 2021 cited 22×
- A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer 2022 cited 19×
- Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) 2023 cited 14×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JLCE for your work?
This journal is guided by Jonathan Riess (University of California, Davis Medical School) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.